Lp082 protects mice against DSS-induced colitis by lowering IL-1β, IL-6, TNF-α, MPO, and IFN-γ levels while boosting IL-10, TGF-β1, and TGF-β2 and blocking the NF-κB signaling pathway. Here, IL6 is linked to colitis.